X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (54371) 54371
Publication (8758) 8758
Book Chapter (622) 622
Book Review (465) 465
Conference Proceeding (121) 121
Book / eBook (58) 58
Dissertation (53) 53
Magazine Article (18) 18
Data Set (9) 9
Web Resource (9) 9
Government Document (8) 8
Reference (7) 7
Trade Publication Article (7) 7
Newspaper Article (4) 4
Streaming Video (2) 2
Newsletter (1) 1
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (31938) 31938
animals (24336) 24336
index medicus (24002) 24002
recombinant fusion proteins - metabolism (13865) 13865
biochemistry & molecular biology (13048) 13048
mice (11633) 11633
cell biology (10475) 10475
recombinant fusion proteins - genetics (9575) 9575
proteins (9169) 9169
molecular sequence data (8311) 8311
female (7521) 7521
male (7383) 7383
amino acid sequence (7373) 7373
oncology (7062) 7062
cell line (6989) 6989
expression (6140) 6140
research (5806) 5806
mutation (5132) 5132
fusion (4898) 4898
gene expression (4693) 4693
article (4678) 4678
transfection (4655) 4655
protein binding (4626) 4626
cancer (4546) 4546
analysis (4506) 4506
phosphorylation (4170) 4170
rats (4139) 4139
recombinant fusion proteins - chemistry (4007) 4007
hematology (3929) 3929
base sequence (3921) 3921
cells (3891) 3891
cells, cultured (3852) 3852
multidisciplinary sciences (3841) 3841
protein (3776) 3776
apoptosis (3754) 3754
fusion protein (3754) 3754
cell line, tumor (3673) 3673
physiological aspects (3603) 3603
signal transduction (3600) 3600
research article (3533) 3533
genetic aspects (3481) 3481
immunology (3257) 3257
activation (3213) 3213
middle aged (3176) 3176
adult (3090) 3090
gene (3087) 3087
virology (2949) 2949
protein structure, tertiary (2921) 2921
biotechnology & applied microbiology (2883) 2883
binding sites (2878) 2878
identification (2816) 2816
health aspects (2800) 2800
microbiology (2738) 2738
recombinant fusion proteins - biosynthesis (2566) 2566
genetics & heredity (2544) 2544
biophysics (2534) 2534
kinetics (2490) 2490
cloning, molecular (2487) 2487
binding (2442) 2442
genes (2442) 2442
hela cells (2410) 2410
aged (2378) 2378
pharmacology & pharmacy (2369) 2369
medicine (2354) 2354
biology (2276) 2276
oncogene proteins, fusion - genetics (2276) 2276
in-vivo (2223) 2223
viruses (2184) 2184
in-vitro (2162) 2162
recombinant fusion proteins - pharmacology (2122) 2122
models, molecular (2091) 2091
leukemia (2078) 2078
cell fusion (2030) 2030
fusion proteins, bcr-abl - genetics (2003) 2003
life sciences (2003) 2003
escherichia-coli (1993) 1993
blotting, western (1988) 1988
membrane fusion (1988) 1988
kinases (1963) 1963
enzyme inhibitors - pharmacology (1961) 1961
time factors (1955) 1955
tumor cells, cultured (1952) 1952
imatinib mesylate (1943) 1943
science (1940) 1940
escherichia coli - genetics (1898) 1898
tumors (1882) 1882
medicine, research & experimental (1869) 1869
gene-expression (1864) 1864
recombinant fusion proteins - therapeutic use (1858) 1858
care and treatment (1825) 1825
peptides (1815) 1815
neurosciences (1806) 1806
treatment outcome (1803) 1803
membrane-fusion (1747) 1747
inhibition (1744) 1744
antibodies (1731) 1731
enzymes (1715) 1715
sequence homology, amino acid (1713) 1713
biochemistry (1668) 1668
cell membrane - metabolism (1664) 1664
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (29) 29
Online Resources - Online (9) 9
Robarts - Stacks (6) 6
Trinity College (John W Graham) - Stacks (5) 5
UofT at Mississauga - Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Closed Orders (4) 4
Engineering & Comp. Sci. - Stacks (3) 3
UTL at Downsview - May be requested (3) 3
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Earth Sciences (Noranda) - Stacks (2) 2
Aerospace - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Cancelled Order (1) 1
Engineering & Comp. Sci. - Reference (1) 1
UofT at Mississauga - Reference (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (54072) 54072
Chinese (174) 174
French (119) 119
Japanese (90) 90
German (84) 84
Russian (57) 57
Spanish (45) 45
Polish (14) 14
Korean (10) 10
Czech (8) 8
Hungarian (8) 8
Portuguese (7) 7
Danish (6) 6
Dutch (3) 3
Finnish (3) 3
Italian (3) 3
Hebrew (2) 2
Swedish (2) 2
Bosnian (1) 1
Croatian (1) 1
Nepali (1) 1
Romanian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Investigation, ISSN 0021-9738, 05/2009, Volume 119, Issue 5, pp. 1109 - 1123
Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | MALIGNANT GLIOMA-CELLS | BLAST CRISIS | CLINICAL RESISTANCE | BCR-ABL MUTATIONS | ENDOPLASMIC-RETICULUM | CYTOCHROME-C RELEASE | CASPASE ACTIVATION | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Transcription Factor CHOP - genetics | Neoplastic Stem Cells - cytology | Gene Expression - drug effects | Calcium - metabolism | Gene Expression - genetics | Microtubule-Associated Proteins - metabolism | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Endoplasmic Reticulum - metabolism | Antineoplastic Agents - therapeutic use | Autophagy - physiology | Thiazoles - therapeutic use | Autophagy - drug effects | Chloroquine - pharmacology | Neoplastic Stem Cells - metabolism | RNA Interference | Endoplasmic Reticulum - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Macrolides - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Dasatinib | Chloroquine - therapeutic use | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Mice, Inbred C3H | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Cell Death - physiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Macrolides - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Causes of | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Drug therapy | Phagocytosis
Journal Article
Chemical Biology & Drug Design, ISSN 1747-0277, 01/2011, Volume 77, Issue 1, pp. 1 - 11
The BCR‐ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia. However, drug resistance caused by kinase domain mutations has... 
kinase | ponatinib | AP24534 | drug discovery | X‐ray crystallography | structure‐based drug design | X-ray crystallography | Structure-based drug design | Drug discovery | Ponatinib | Kinase | structure-based drug design | C-ABL | CRYSTAL-STRUCTURE | BIOCHEMISTRY & MOLECULAR BIOLOGY | BMS-354825 | DOMAIN MUTATIONS | CANCER | CHRONIC MYELOID-LEUKEMIA | STRATEGIES | THERAPY | IMATINIB | T315I MUTANT | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Piperazines - chemistry | Structure-Activity Relationship | Pyridazines - pharmacology | Pyridazines - chemical synthesis | Pyrimidines - chemistry | Protein Kinase Inhibitors - chemistry | Protein Binding - drug effects | Imidazoles - chemical synthesis | Imidazoles - therapeutic use | Pyridazines - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Imidazoles - pharmacology | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Animals | Mutation - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Benzamides | Fluoroimmunoassay | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Drug resistance | Analysis | Leukemia | STRUCTURE-ACTIVITY RELATIONSHIPS | MUTANTS | BASIC BIOLOGICAL SCIENCES | ENZYME INHIBITORS | TYROSINE | GENE MUTATIONS | PHOSPHOTRANSFERASES | MYELOID LEUKEMIA | MUTATIONS | ANTINEOPLASTIC DRUGS | 60 APPLIED LIFE SCIENCES | RESIDUES
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2013, Volume 19, Issue 1, pp. 279 - 290
Journal Article
International Journal of Cancer, ISSN 0020-7136, 2014, Volume 134, Issue 6, pp. 1484 - 1494
Crizotinib is an oral tyrosine kinase inhibitor approved for treating patients with non-small cell lung cancer (NSCLC) containing an anaplastic lymphoma kinase... 
brain accumulation | crizotinib | P‐glycoprotein | ALK inhibitor | elacridar | P-glycoprotein | LUNG | EML4-ALK FUSION GENE | METASTASES | PENETRATION | GF120918 | COMBINATION | ANAPLASTIC LYMPHOMA KINASE | PHARMACOKINETICS | ONCOLOGY | MULTIDRUG-RESISTANCE | PHASE-I | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Pyridines - pharmacokinetics | Biological Availability | Male | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Neoplasm Proteins - metabolism | ATP-Binding Cassette Transporters - physiology | Brain - metabolism | Tissue Distribution | ATP-Binding Cassette Transporters - genetics | ATP-Binding Cassette Transporters - metabolism | Drug Therapy, Combination | Neoplasm Proteins - genetics | Pyrazoles - pharmacokinetics | Pyrazoles - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Tetrahydroisoquinolines - pharmacology | Administration, Oral | Cells, Cultured | Mice, Knockout | Brain - drug effects | Animals | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Acridines - pharmacology | ATP Binding Cassette Transporter, Sub-Family B | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Plasma | Chemotherapy | Brain cancer | Rodents | Lymphomas | Glycoproteins | Metastasis
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 747 - 757
Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a... 
SURVIVAL | MAJOR MOLECULAR RESPONSE | TREATMENT-FREE REMISSION | ONCOLOGY | IMATINIB DISCONTINUATION | DISEASE | FOLLOW-UP | DASATINIB | WITHDRAWAL SYNDROME | NILOTINIB | PHASE-2 TRIAL | Predictive Value of Tests | Prospective Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Clinical Decision-Making | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Polymerase Chain Reaction | Adult | Female | Biomarkers, Tumor - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Drug Administration Schedule | Risk Assessment | Europe | Risk Factors | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Progression-Free Survival | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Antimitotic agents | Tyrosine | Antineoplastic agents | Analysis | Life Sciences | Hematology | Human health and pathology | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Cancer Discovery, ISSN 2159-8274, 04/2017, Volume 7, Issue 4, pp. 400 - 409
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or... 
REARRANGEMENT | ONCOGENE | ONCOLOGY | ANALOG SECRETORY CARCINOMA | LANDSCAPE | KINASE FUSIONS | SARCOMAS | ETV6-NTRK3 GENE FUSION | CRIZOTINIB | GENOMIC ALTERATIONS | CLINICAL-RESPONSE | Benzamides - pharmacokinetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Receptor, trkA - antagonists & inhibitors | Male | Receptor, trkB - genetics | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Mammary Analogue Secretory Carcinoma - genetics | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Membrane Glycoproteins - antagonists & inhibitors | Receptor, trkC - genetics | Anaplastic Lymphoma Kinase | Melanoma - genetics | Colorectal Neoplasms - drug therapy | Receptor, trkB - antagonists & inhibitors | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Benzamides - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Crizotinib | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Pyridines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Receptor, trkC - antagonists & inhibitors | Melanoma - pathology | Mammary Analogue Secretory Carcinoma - drug therapy | Membrane Glycoproteins - genetics | Protein Kinase Inhibitors - administration & dosage | Sequestosome-1 Protein - genetics | Pyrazoles - administration & dosage | Indazoles - pharmacokinetics | Receptor Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - genetics | Melanoma - drug therapy | Adolescent | Receptor, trkA - genetics | Oncogene Proteins, Fusion - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Indazoles - adverse effects | Colorectal Neoplasms - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Nature, ISSN 0028-0836, 03/2017, Volume 543, Issue 7647, pp. 733 - 737
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 04/2012, Volume 122, Issue 4, pp. 1377 - 1392
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 05/2015, Volume 125, Issue 5, pp. 1780 - 1789
Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases. Currently, more than 25 oncology drugs that target... 
MEDICINE, RESEARCH & EXPERIMENTAL | ONCOGENIC ACTIVATION | PROTEIN-KINASE | TUMOR-INFILTRATING MACROPHAGES | ADAPTIVE RESISTANCE | ACQUIRED-RESISTANCE | CLINICAL RESISTANCE | DIACYLGLYCEROL KINASES | RECEPTOR TYROSINE KINASE | IMATINIB MESYLATE | ANTITUMOR EFFICACY | Immunotherapy - methods | Apoptosis - drug effects | Humans | Substrate Specificity | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Neoplasms - genetics | Protein Processing, Post-Translational - drug effects | Drug Design | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Molecular Targeted Therapy - methods | Neoplasms - enzymology | Gene Fusion | Enzyme Activation - drug effects | Neoplasms - drug therapy | Drug Synergism | Point Mutation | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Oncogene Proteins, Fusion - antagonists & inhibitors | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Apoptosis - physiology | Enzyme inhibitors | Physiological aspects | Research | Drug therapy | Phosphotransferases | Health aspects | Cancer | Proteins | Phosphorylation | Gene amplification | Biology | Regulation | Genomes | Mutation | Metastasis | Kinases | Phosphatase | Tumors | Review
Journal Article